License Agreement with Celera Corporation on five cancer target molecules

New license for oncology research

Bayer Schering Pharma, Berlin, has further intensified its oncology research. These activities include the signing this summer of an exclusive license agreement with California-based Celera Corporation that provides Bayer Schering Pharma with access to five novel targets for the development of both cancer therapies and new cancer diagnostic procedures. “This agreement allows us to expand our existing research portfolio in the area of cancer-related targets,” said Professor Khusru Asadullah, Head of Target Discovery at Bayer Schering Pharma. “We look forward to exploring the full potential of these promising target candidates with regard to therapeutic interference for anti-tumor therapy as well as in in-vivo diagnostic imaging.”

Bayer Schering Pharma acquired the license in exchange for a one-time fee for the exclusive access to the five targets. Additional payments will be due if products resulting from this research are successfully commercialized.

Celera is a health care business delivering personalized disease management through a combination of products and services.